Stocky turns companies like AbCellera Biologics Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. ABCL's 29/100 composite score reflects a Value Compounder Score of just 23/100, signaling weak underlying business fundamentals and limited margin expansion. While Leadership Alignment is respectable at 69/100, the core vulnerability—heavy dependence on partner execution for milestone payments and royalties—creates structural risk that outweighs governance strength. Revenue visibility hinges on external clinical and regulatory outcomes beyond management control.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for AbCellera Biologics Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 29/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates AbCellera Biologics Inc. (ABCL) at 29/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. ABCL's 29/100 composite score reflects a Value Compounder Score of just 23/100, signaling weak underlying business fundamentals and limited margin expansion. While Leadership Alignment is respectable at 69/100, the core vulnerabi
ABCL's current Stocky Verdict is 29/100, placing it in the "Avoid" band. This composite combines a 23/100 Compounder score, 69/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for AbCellera Biologics Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
AbCellera Biologics Inc. scores 69/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
AbCellera Biologics Inc.'s Vulnerability Profile scores 25/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to AbCellera Biologics Inc..
Sign up free and unlock the full analysis on ABCL — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for ABCL in the app.
